Researchers have revealed the role of enzyme TYK2 in the aggregation of tau proteins, which contributes to Alzheimer’s ...

Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) launched the "Healthy Steps" National Health Literacy Initiative at ...

UST, a leading digital transformation solutions company, has opened a new office and state-of-the-art Generative AI Experience Center in Cyberjaya, Selangor, Malaysia. This facility will act as a hub ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Researchers found that inhibiting the enzyme TYK2 may reduce the harmful accumulation of tau protein in Alzheimer’s disease, ...

Baricitinib, an inhibitor of JAK1/2, was approved by both the FDA and European Medicines Agency in 2022 to treat moderate to ...

Topline results are anticipated in 2026. The Phase 1 clinical study of A-005, a potential first-in-class, central nervous system (CNS) penetrant TYK2 inhibitor being developed for the treatment of ...

The phosphodiesterase 5 inhibitor mirodenafil, a drug from the Viagra family, could have beneficial effects on cognition ...

TYK2 enzyme changes tau protein from a protective role to a harmful one, contributing to Alzheimer’s disease progression.

To this end, we are encouraged by the fact that others have developed TYK2 inhibitors that have been tested in humans for other indications. Studies are needed to see if these inhibitors indeed get ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas ...